Fenwick & West represented Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, in its $65 million Series C financing. The financing was co-led by existing investor Sofinnova Ventures and new investor Redmile Group. Additional new investors include RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., Rock Springs Capital Management LP, Cormorant Asset Management LLC, Cowen Private Investments and Foresite Capital. Existing investors OrbiMed, 5AM Ventures, Versant Ventures, Deerfield Management Company and Venrock also participated. Cowen and Company served as exclusive placement agent for the financing.
The new capital will be used primarily to advance the company’s three lead development programs to key clinical milestones and to establish internal GMP manufacturing capabilities.
The Fenwick transaction team was led by partners Effie Toshav, Matthew Rossiter and Stefano Quintini and corporate associates Matthew Karwoski, Allison Cooper and Liz Federowicz.